Mechanism of antiviral action of (E)-5-(2-bromovinyl)-2'deoxyuridine (BVDU): Direct evidence with [14C]BVDU in herpes simplex virus-infected cells

Antiviral Chemistry and Chemotherapy

Volumn 8, Issue 6, 1997, Pages 565-571

  Ciucci, A ^a   Iafrate, E M ^a   Manzini, S ^a   Giachetti, A ^a  

^a Menarini Ricerche SpA   (Italy)

Author keywords

14C BVDU; Drug metabolism; Herpes simplex virus; Thymidine kinase; Viral DNA

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; ANTIVIRUS AGENT;

ANTIVIRAL ACTIVITY; ARTICLE; BIOACCUMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SELECTIVITY; HERPES; HERPES SIMPLEX VIRUS 1; PRIORITY JOURNAL; RADIOACTIVITY;

EID: 0030734960     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Allaudeen HS, Kozarich JW, Bertino JR & De Clercq E (1981) On the mechanism of selective inhibition of herpesvirus replication by E-5-(2-bromovinyl)-2′-deoxyuridine. Proceedings of the National Academy of Sciences, USA 78: 2698-2702.
2. Allaudeen HS, Chen MS, Lee JJ, De Clercq E & Prusoff HW (1982) Incorporation of E-5-(2-halovinyl)-2′-deoxyuridines into deoxyribonucleic acids of herpes simplex virus type 1 infected cells. Journal of Biological Chemistry 257: 603-606.
3. Ayisi NK, De Clercq E, Wall RA, Hughes H & Sack SL (1984) Metabolic fate of E-5-(2-bromovinyl) 2′ deoxyuridine in herpes simplex virus and mock infected cells. Antimicrobial Agents and Chemotherapy 26: 762-765.
4. Ayisi, NK, Wall RA, Wanklin RJ, Machida H, De Clercq E & Sack SL (1987) Comparative metabolism of (E)-5-(2-bromovinyl)-2′-deoxyuridine and 1 β-D-Arabinofuranosyl-(E)-5-2-bromovinyl)-2′-deoxyuridine in HSV infected cells. Molecular Pharmacology 31: 422-429.
5. Balzarini J & De Clercq E (1989) Inhibitory effects of E-5-(2-bromovinyl)-2′-deoxyuridine. (BVDU) and related compounds on herpes simplex virus (HSV) infected cells and HSV thymidine kinase gene trasformed cells. Methods and Findings in Experimental and Clinical Pharmacology 11: 379-382.
6. Cheng YC (1984) Herpes simplex virus thymidine kinases-dependent antiviral agents. In Antiviral Drugs and Interferon: the Molecular Basis of their Activity. Edited by Y Becker. Boston & The Hague: Martinus Nijhoff, pp. 59-70.
7. Cheng YC, Dutschman G, De Clercq E, Jones AS, Rahim SG, Verhelst G & Walker RT (1981) Differential affinities of 5-(2-halogenovinyl)-2′deoxyuridines for deoxythymidine kinases of various origins. Molecular Pharmacology 20: 230-233.
8. De Clercq E (1982) Comparative efficacy of antiherpes drugs in different cell lines. Antimicrobial Agents and Chemotherapy 21: 661-663.
9. De Clercq E (1984) Biochemical aspects of the selective antiherpes activity of nucleoside analogues. Biochemical Pharmacology 33: 2159-2169.
10. De Clercq E (1986) Towards a selective chemotherapy of virus infections. Development of bromovinyldeoxyuridine as a highly potent and selective antiherpetic drug. Academie Voor Geneeskunde Van Belgie 48: 261-290.
11. De Clercq E (1993) Antiviral agents: characteristic activity spectrum depending on the molecular target with which they interact. Advances in Virus Research 42: 1-55.
12. De Clercq E, Descamps J, De Somer J, Barr PJ, Jones AS & Walker RT (1979) E-5-(2-bromovinyl)-2′deoxyiuridine: a potent and selective anti-herpes agent. Proceedings of the National Academy of Sciences, USA 76: 2947-2951.
13. De Clercq E, Descamps J, Verhelst G, Walker RT, Jones AS, Torrence PF & Shugar D (1980a) Comparative efficacy of antiherpes drugs against different strains of herpes simplex virus. Journal of Infectious Disease 141: 563-574.
14. De Clercq E, Descamps J, Verhelst G, Jones AS & Walker RT (1980b) Antiviral activity of 5-(2-halogenous)-2′-deoxyuridines. In Current Chemotherapy and Infectious Disease, vol 2. Edited by JD Nelson and C Grassi. Washington, D.C.: American Society for Microbiology, pp. 1372-1374.
15. De Clercq E, Descamps J, Ogata M & Shigeta S (1982) In vitro susceptibility of varicella-zoster virus to E-5-(2-bromovinyl)-2′-deoxyuridine: related compound. Antimicrobial Agents and Chemotherapy 21: 33-38.
16. De Clercq E, Bernaerts R, Balzarini J, Herdewijn P & Verbruggen A (1985a) Metabolism of the carbocyclic analogue of E-5-(2-iodovinyl)-2′deoxyuridine in herpes simplex virus infected cells. Incorporation of C-IVDU into DNA. Journal of Biological Chemistry 260: 10621-10628.
17. -) herpes simplex virus: target at thymidylate synthase. Molecular Pharmacology 32: 286-292.
18. Descamps J & De Clercq E (1981) Specific phosphorylation of (E)-5-(2-iodovinyl)-2′-deoxyuridine by herpes simplex virus infected cells. Journal of Biological Chemistry 256: 5973-5976.
19. Iafrate EM, Ciucci A, Manzini S & Giachetti A (1997) In vitro antiherpetic activity of brivudin: effect of variable exposure times and evaluation of drug interaction. Antiviral Research 34: A77.
20. Mancini W, De Clercq E & Prusoff WH (1983) The relationship between incorporation of E-5-(2-bromovinyl)-2′deoxyuridine into herpes simplex virus type 1 DNA with virus infectivity and DNA integrity. Journal of Biological Chemistry 258: 792-795.
21. Spadari S, Ciarrocchi G, Focher F, Verri A, Maga G, Arcamone F, Iafrate E, Manzini S, Garbesi A & Tondelli L (1995) 5 Iodo-2′-deoxy-L-uridine and E-5-(2-bromovinyl)-2′deoxy-L-uridine: selective phosphorylation by herpes simplex virus type 1 thymidine kinase, antiherpetic activity and cytotoxicity studies. Molecular Pharmacology 47: 1231-1238.
22. Vere Hodge RA & Perkins RM (1989) Mode of action of 9-(4-hydroxy-3-hydroxymethylbut-1-yl) guanine (BRL 39123) against herpes simplex virus in MRC-5 cells. Antimicrobial Agents and Chemotherapy 33: 223-229.
23. - strains) infected cells. Molecular Pharmacology 31: 493-499.